Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | HTR3A | P46098 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 3/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359045 | 0.74 | CYP11B1 (0.60) | CHRNB2CHRNA4HTR1AHTR7HTR2B | |
| SCHEMBL13094488 | 0.73 | HTR2C (0.89) | HTR2CROCK1 | |
| SCHEMBL30725496 | 0.73 | HTR2C (0.56) | HTR2CHTR1AHTR7HTR3AHTR6 | |
| SCHEMBL9303783 | 0.73 | HTR2C (0.56) | HTR2CHTR1AHTR7HTR3AHTR6 | |
| SCHEMBL6263602 | 0.67 | CYP11B1 (0.66) | HTR2CHTR1AHTR7HTR3AHTR6 | |
| SCHEMBL30297584 | 0.66 | HTR2C (1.00) | HTR2C | |
| SCHEMBL16707784 | 0.66 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNA1CHRNA7HTR1A | |
| SCHEMBL1026755 | 0.66 | HTR2C (1.00) | HTR2C | |
| SCHEMBL5756036 | 0.66 | — | — | |
| SCHEMBL6094605 | 0.65 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2215080-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, BDKRB2 | HTR2C 268/4885CHRNB2 187/4885CHRNA4 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.